pf-06688992
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 16, 2017 (NCT03159117)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Ganglioside GD3Immunity, passive
Ganglioside GD3 immunity, passive
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594487 ↗
Also known as
- pf-06688992
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03159117 | Phase 1 | May 16, 2017 | Cornell University, Pfizer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Pfizer | For profit | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1